The acquisition brings two best-in-class endocrine assets with blockbuster potential, expanding the acquirer's portfolio and supporting sustained revenue growth. The $10B deal is expected to close in Q3 2026, with strong physician support and significant synergies anticipated.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.